San Francisco · CA, USA · founded 2021 · https://nirvahealth.com
Diligence memoA one-page analyst read on Nirva — recommendation, valuation, rhythm, risks.→Nirva: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
The lifestyle medicine layer for clinicians.
Nirva is the lifestyle medicine layer for clinicians. For the first time, any doctor can offer daily care between appointments and earn recurring revenue. 87% of patients improve in weeks, and our system is discovering things like which foods trigger hot flashes, insights that no existing research has found.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Nirva is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Play Health Perimenopause Care Platform | Biotech | — | — | 72% |
| Saatvy Root cause help for chronic conditions | — | — | — | 72% |
| Galen AI Personal AI healthcare agent, powered by clinical and wearable data. | AI / ML | — | — | 72% |
| CurvaFix, Inc. | Other Health Care | Series C | $478.1M | 72% |
| Northwind Tele-dermatology for chronic skin conditions | Healthtech | — | — | 71% |
| LifestyleRx Virtual Care for Type 2 Diabetes Reversal | Insurance | — | — | 71% |
| Prana An AI primary care doctor in your pocket | Mobility / Logistics | — | — | 70% |
| NimbleRx On-demand prescription delivery. | SaaS / Software | — | — | 70% |
See where Nirva sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Nirva, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.